83 related articles for article (PubMed ID: 24257547)
1. Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Piek JM
Int J Gynecol Cancer; 2013 Oct; 23(8):1348. PubMed ID: 24257547
[No Abstract] [Full Text] [Related]
2. Reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Wang P; Cheng X; Fu Z; Zhou C; Lu W; Xie X
Int J Gynecol Cancer; 2013 May; 23(4):622-9. PubMed ID: 23446378
[TBL] [Abstract][Full Text] [Related]
3. The prognostic values of matrix metalloproteinases in ovarian cancer.
Zeng L; Qian J; Zhu F; Wu F; Zhao H; Zhu H
J Int Med Res; 2020 Jan; 48(1):300060519825983. PubMed ID: 31099295
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
De Donato M; Petrillo M; Martinelli E; Filippetti F; Zannoni GF; Scambia G; Gallo D
Gynecol Oncol; 2017 Jul; 146(1):170-178. PubMed ID: 28495238
[TBL] [Abstract][Full Text] [Related]
5. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
6. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
[No Abstract] [Full Text] [Related]
7. Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer.
Katso RM; Manek S; Biddolph S; Whittaker R; Charnock MF; Wells M; Ganesan TS
Cancer Res; 1999 May; 59(10):2265-70. PubMed ID: 10344726
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression].
Blok R; Blok K; Jeleń M; Gryboś M
Ginekol Pol; 2004 Feb; 75(2):91-8. PubMed ID: 15108579
[TBL] [Abstract][Full Text] [Related]
9. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
10. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.
Linder N; Bützow R; Lassus H; Lundin M; Lundin J
Gynecol Oncol; 2012 Feb; 124(2):311-8. PubMed ID: 22044687
[TBL] [Abstract][Full Text] [Related]
11. [Expression of THY1 gene in epithelial ovarian cancer].
Zeng LQ; Peng ZL; Duan ZL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
[TBL] [Abstract][Full Text] [Related]
12. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
13. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
15. [Expression of cyclooxygenase-2 in ovarian carcinoma and its significance].
Luo WZ; Shen J; Zhang Y; Lang JH
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(16):1374-6. PubMed ID: 15637815
[No Abstract] [Full Text] [Related]
16. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
17. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
18. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
